Benchmark Boosts Amedisys (NASDAQ:AMED) Price Target to $250.00

Amedisys (NASDAQ:AMED) had its price target upped by Benchmark from $210.00 to $250.00 in a research report report published on Thursday morning, BenzingaRatingsTable reports. They currently have a buy rating on the health services provider’s stock.

AMED has been the topic of several other reports. BidaskClub raised Amedisys from a hold rating to a buy rating in a research report on Saturday, July 18th. UBS Group dropped their price objective on Amedisys from $208.00 to $190.00 and set a neutral rating on the stock in a report on Monday, May 11th. SunTrust Banks lifted their target price on shares of Amedisys from $240.00 to $260.00 and gave the company a buy rating in a research note on Friday, July 10th. Zacks Investment Research upgraded shares of Amedisys from a hold rating to a buy rating and set a $193.00 price target on the stock in a research note on Friday, May 1st. Finally, Raymond James lifted their price objective on shares of Amedisys from $210.00 to $255.00 and gave the company an outperform rating in a research note on Thursday. Five equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Amedisys has a consensus rating of Buy and a consensus target price of $215.67.

NASDAQ AMED opened at $234.16 on Thursday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.02 and a quick ratio of 1.48. The firm has a market capitalization of $7.58 billion, a price-to-earnings ratio of 60.66, a price-to-earnings-growth ratio of 3.44 and a beta of 0.95. The company has a 50 day simple moving average of $202.10 and a 200-day simple moving average of $187.33. Amedisys has a 52-week low of $121.00 and a 52-week high of $237.28.

Amedisys (NASDAQ:AMED) last released its earnings results on Tuesday, July 28th. The health services provider reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.81 by $0.53. Amedisys had a net margin of 6.50% and a return on equity of 22.41%. The company had revenue of $485.06 million during the quarter, compared to the consensus estimate of $468.38 million. During the same quarter in the prior year, the firm earned $1.21 EPS. The company’s revenue was down 1.6% compared to the same quarter last year. On average, analysts predict that Amedisys will post 4.84 EPS for the current year.

In other Amedisys news, COO Christopher Gerard sold 750 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $203.43, for a total value of $152,572.50. Following the sale, the chief operating officer now directly owns 33,573 shares in the company, valued at approximately $6,829,755.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Denise M. Bohnert sold 362 shares of the business’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $220.00, for a total transaction of $79,640.00. Following the transaction, the insider now owns 9,095 shares in the company, valued at approximately $2,000,900. The disclosure for this sale can be found here. Insiders sold a total of 38,693 shares of company stock worth $6,882,126 in the last ninety days. Insiders own 2.90% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AMED. APG Asset Management N.V. acquired a new position in Amedisys in the 1st quarter valued at approximately $9,616,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Amedisys during the first quarter valued at approximately $60,000. Royal Bank of Canada raised its stake in shares of Amedisys by 42.8% in the first quarter. Royal Bank of Canada now owns 41,113 shares of the health services provider’s stock valued at $7,546,000 after purchasing an additional 12,313 shares in the last quarter. Swiss National Bank raised its stake in shares of Amedisys by 1.8% in the first quarter. Swiss National Bank now owns 62,600 shares of the health services provider’s stock valued at $11,490,000 after purchasing an additional 1,100 shares in the last quarter. Finally, BNP Paribas Arbitrage SA lifted its position in Amedisys by 115.5% in the first quarter. BNP Paribas Arbitrage SA now owns 19,510 shares of the health services provider’s stock worth $3,581,000 after purchasing an additional 10,458 shares during the period. Institutional investors and hedge funds own 88.31% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Read More: Certificate of Deposit (CD) For Risk Adverse Investors?

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.